Identification of RNase L-Dependent, 3’-End-Modified, Viral Small RNAs in Sindbis Virus-Infected Mammalian Cells

Erika Girardi, Béatrice Chane-Woon-Ming, Mélanie Messmer, Pasi Kaukinen,* Sébastien Pfeffer

Architecture and Reactivity of RNA, Institut de Biologie Moléculaire et Cellulaire du CNRS, Université de Strasbourg, Strasbourg, France

* Present address: Pasi Kaukinen, Department of Food and Environmental Sciences, University of Helsinki, Helsinki, Finland.

ABSTRACT Small RNAs play a critical role in host-pathogen interaction. Indeed, small RNA-mediated silencing or RNA interference (RNAi) is one of the earliest forms of antiviral immunity. Although it represents the main defense system against viruses in many organisms, the antiviral role of RNAi has not been clearly proven in higher vertebrates. However, it is well established that their response to viral infection relies on the recognition of viral RNAs by host pattern recognition receptors (PRRs) to trigger activation of the interferon pathway. In the present work, we report the existence of a novel small noncoding RNA population produced in mammalian cells upon RNA virus infection. Using Sindbis virus (SINV) as a prototypic arbovirus model, we profiled the small RNA population of infected cells in both human and African green monkey cell lines. Here, we provide evidence for the presence of discrete small RNAs of viral origin that are not associated with the RNA-induced silencing complex (RISC), that are highly expressed and detected by Northern blot analysis, and that accumulate as 21- to 28-nucleotide (nt) species during infection. We report that the cellular antiviral endoribonuclease RNase L cleaves the viral genome, producing in turn the small RNAs. Surprisingly, we uncovered the presence of a modification on the 3’-end of SINV-derived viral small RNAs (SvsRNAs) that might be at the origin of their stability. Altogether, our findings show that stable modified small viral RNAs could represent a novel way to modulate host-virus interaction upon SINV infection.

IMPORTANCE In a continuous arms race, viruses have to deal with host antiviral responses in order to successfully establish an infection. In mammalian cells, the host defense mechanism relies on the recognition of viral RNAs, resulting in the activation of type I interferons (IFNs). In turn, the expression of many interferon-stimulated genes (ISGs) is induced to inhibit viral replication. Here we report that the cytoplasmic, interferon-induced, cellular endoribonuclease RNase L is involved in the accumulation of a novel small RNA population of viral origin. These small RNAs are produced upon SINV infection of mammalian cells and are stabilized by a 3’-end modification. Altogether, our findings indicate that in our system RNA silencing is not active against Sindbis virus (SINV) and might open the way to a better understanding of the antiviral response mediated by a novel class of small RNAs.

In order to successfully establish an infection, viruses engage in a continuous arms race with their hosts, the outcome of which might ultimately result in either viral persistence, clearance of the viral infection, or death of the infected cells. The arsenal of antiviral defenses and viral counter defense mechanisms is vast and very diverse among the different phyla of life. Plants, insects, nematodes, and fungi mostly (if not exclusively) rely upon an innate immune response, whereas mammals have evolved an adaptive response in addition to this first line of defense. In the former organisms, the antiviral component of the innate immune response is mainly based on a highly conserved process commonly referred to as RNA silencing, or RNA interference (RNAi). In this phenomenon, long double-stranded RNAs of viral origin are cleaved by the RNase Dicer into small interfering RNAs (siRNAs), which are then assembled into effector complexes that contain a member of the Argonaute (Ago) family; this results in targeted degradation of viral messenger or genomic RNAs (1).

In mammals, another type of innate immunity has evolved to control viruses (2). The initial recognition of nonself viral nucleic acids by extra- and intracellular sensors triggers the activation of type I interferons (IFNs) (3). This leads in turn to the upregulation of numerous IFN-stimulated genes (ISGs) (4), which either directly trigger a signaling cascade directed against the viral infection or mobilize other cells of the immune system. ISGs encode proteins involved in apoptosis induction, protein synthesis blocking, or in the regulation of mRNA editing or RNA degradation (5). One key factor involved in IFN type I-mediated host defense is RNase L, a latent cytoplasmic endoribonuclease that is activated by 2’,5’-oligoadenylates in response to double-stranded RNA (dsRNA) sensing and that cleaves both viral and cellular RNAs (6).
Although extensive deep sequencing analyses have been performed to identify siRNAs in mammalian cells infected with several RNA viruses, there is so far no good evidence for a possible antiviral role of RNAi in mammalian somatic cells (7). Nevertheless, another class of small noncoding RNAs, microRNAs (miRNAs), has been shown to play an important role during viral infection in mammals. miRNAs are evolutionarily conserved small RNAs derived from large primary transcripts, which are sequentially processed by the respective nuclear and cytoplasmic RNase III enzymes, Drosha and Dicer, to generate mature single-stranded ~21- or 22-nucleotide (nt) RNAs (8, 9). Similar to siRNAs, they are incorporated into an effector Ago-containing RNA-induced silencing complex (RISC), whereby they mediate posttranscriptional regulation of target mRNAs via partially complementary sites (10). On one hand, miRNAs of cellular origin can directly or indirectly regulate viral infections (11, 12). On the other hand, some viruses have evolved the capacity to encode their own miRNAs, which represent an ideal tool to stealthily modulate the cellular environment. To date, viral miRNAs have been almost exclusively identified in the genomes of DNA viruses, mostly herpesviruses (13–17), with the notable exception of bovine leukemia virus, a retrovirus with an RNA genome (18). It has been commonly assumed that cytoplasmic RNA viruses cannot encode miRNAs, not only because they do not have access to the nuclear biogenesis machinery but also because their genomic integrity would be destabilized by miRNA processing (19). Nevertheless, it has recently been demonstrated that the insertion of a cellular miRNA precursor into the 3′-end nontranslated region (NTR) of Sindbis virus (SINV) genomic RNA leads to its cytoplasmic processing without affecting the viral replication (20, 21).

The arthropod-borne SINV is a small, enveloped, positive, single-stranded RNA virus and is the prototype for the alphavirus genus. Alphaviruses represent a group of widely distributed human and animal pathogens, which pose a serious public health threat (22). Some of them induce febrile and arthritogenic diseases, while others can cause highly debilitating diseases, such as encephalitis. The SINV genomic RNA is capped and polyadenylated and is infectious as naked RNA. Upon entry into the cytoplasm by endocytosis, the host translational machinery recognizes the genomic RNA, and four nonstructural proteins are produced (23). Their expression is sufficient for the establishment of replication complexes and the synthesis of a complementary antiviral RNA strand. The antigenome is necessary for the replication of the viral genome and the production of a subgenomic RNA that ensures the translation of the structural proteins during the late phase of infection (24, 25).

To date, SINV has not been shown to give rise to any small RNA species in mammalian cells. As such, we decided to investigate the small RNA profile of SINV-infected human and African green monkey cell lines. Using small RNA cloning and deep sequencing techniques, we provide evidence that the SINV genome is a source of small RNAs in infected mammalian cells. Some of these small RNAs accumulate to levels detected by Northern blot analysis. We set out to identify the factors involved in their biogenesis and show that they do not depend on the RNA silencing machinery, but rather, that they are downstream products of the cytoplasmic IFN-induced endoribonuclease RNase L. Finally, we also present experimental evidence that these viral small RNAs are modified at their 3′ extremity. Altogether, our results indicate that the SINV-derived small RNAs could represent key markers of the host defense mechanism.

RESULTS
SINV-derived small RNAs accumulate in infected mammalian cells. In order to investigate the presence and nature of virus-derived small RNAs in mammalian cells, we used a small RNA cloning and deep sequencing approach. We generated and analyzed small RNA libraries from both HEK293 and Vero cells infected with SINV or not infected with SINV.

Total RNA was isolated from uninfected cells or cells infected with SINV at a multiplicity of infection (MOI) of 0.01 plaque forming units (PFU) per cell 16 h postinfection (hpi). Using these conditions, we could detect cells with a high viral load without observing any apparent cell death as assessed by propidium iodide staining (see Fig. S1 in the supplemental material). We also confirmed that until 24 hpi, cells were still actively proliferating (data not shown). High-throughput sequencing yielded 201,793 and 1,193,893 reads that mapped to the SINV genome in infected HEK293 and Vero cells, respectively (Fig. 1A); these two numbers of reads represented a percentage of 1.66 and 7.99%, respectively, of total mapped small RNAs in HEK293 and Vero cells. The greater fraction of viral reads in Vero cells is consistent with the fact that these cells are known to be more permissive to viral infections due to a defect in interferon production (26). The distribution of the reads on the viral genomic (positive) and antigenomic (negative) strands is indicated in Fig. 1A. Interestingly, the vast majority of the reads (98 to 99%) originate from the genomic strand of the virus. Nonetheless, we identified limited sequencing reads that were derived from the negative strand, albeit at extremely low levels in both libraries (Fig. 1A). Their genomic distribution showed a peak at the 3′ end of the antigenome (see Fig. S2A in the supplemental material). This specific region corresponds to the viral promoter, necessary for the replication of the viral genome and is known to fold into a conserved 44-nt stem-loop structure (25). The length distribution of the antigenomic small RNA reads peaked at a size of 22 nt (Fig. S2B), which corresponds to the 5′ arm of the stem-loop structure (Fig. S2C). Although we could validate the presence of the 44-nt-long RNA by Northern blot analysis, we were unable to detect the accumulation of the small 22-nt RNA as a discrete species (Fig. S2D).

The size distribution of the main population of viral reads mapping on the positive strand of the virus was broad with no defined peak at a specific length (Fig. 1B). However, a closer inspection revealed that the overall size and genomic distribution of the viral reads were highly similar in both HEK293 and Vero cells (Fig. 1C). Moreover, a greater number of reads were found between nucleotides 7000 and 11700 of the viral genome, corresponding to the abundantly expressed subgenomic RNA.

We selected 14 candidates among the most abundant peaks obtained in both cell types for validation by Northern blot analysis (see Fig. S3A in the supplemental material). We could detect several SINV-derived viral small RNAs (SvsRNAs) of 20 to 30 nt in length that were derived from all along the viral genome (Fig. S3B). Among them, SvsRNA-1, -2, and -3 were detected in both HEK293 and Vero cells (Fig. S3C). The presence of abundant larger bands accumulating between 40 and 100 nt was also evident. Of note, the expression of both larger and smaller viral RNAs increased proportionally to the accumulation of the viral genome during a time course of infection (Fig. 1D and E). The
identification of SINV-derived small RNAs prompted us to analyze more closely their origin and biochemical properties.

The production of SvsRNAs does not rely on the miRNA biogenesis machinery. The identification of small RNAs from RNA viruses could be seen either as a result of a productive mechanism for the pathogen (as for virus-encoded miRNAs) or as the consequence of a host response to control the infection by degrading viral RNAs. SINV expresses four enzymes that play key functions during the viral replicative cycle. However, none of these enzymes is known to possess an endoribonuclease activity (22) that could enable the processing of small RNAs from a viral RNA precursor. Therefore, cellular enzymes have to be involved in the biogenesis of SINV sRNAs. In order to identify them, we decided to knock down cytoplasmic enzymes with a known RNase activity. We first focused on proteins important for the production of small RNAs, such as miRNAs. Hence, we transfected siRNAs against Drosha, Dicer, or Ago2 followed by an infection with SINV and an analysis of viral small RNA accumulation. Although Drosha is known to be mostly nuclear, we also took it into consideration because it was recently shown to relocalize to the cytoplasm upon SINV infection (21). Although we were able to downregulate very efficiently Drosha, Dicer, and Ago2 (see Fig. S4A to C in the supplemental material), the knockdown of these factors neither affected the viral load nor the accumulation of SvsRNA-1, -2 and -3 (Fig. S4D to G). We also examined whether we could detect an siRNA signature among all viral reads by looking for small RNAs that could perfectly base pair on 19 or 20 nt and present a 2-nt overhang in 3′. A very limited number of such duplexes could be found, but they were not more represented than larger duplexes presenting with 3′ or 5′ overhangs (data not shown). It has been reported that small RNAs, which are not generated by Dicer or Drosha cleavage, could nevertheless be assembled into Argonaute proteins (e.g., tRNA fragments [27]). We therefore immunoprecipitated Argonaute proteins followed by Northern blot analysis to see whether SvsRNAs could be detected within the RISC. However, although we could detect the accumulation of the cellular miRNA miR-16, using both an antibody specific for Ago2 (Fig. S4H, left panel) and an antibody able to recognize all four Ago proteins (Fig. S4H, right panel), we were unable to detect SvsRNAs within immunoprecipitated RISC.

**RNase L is involved in the production of SvsRNAs.** We then hypothesized that an endoribonuclease involved in the antiviral response could be implicated in SvsRNA production. RNase L is a ubiquitous, cytoplasmic, interferon-induced endonuclease that plays a key role in the cellular response to viral infections. It cleaves single-stranded RNA regions after the dinucleotides UA/UU,
was unlikely that the identified small RNAs were direct products of this enzyme. We therefore looked for other factors implicated in RNA degradation that could affect SvsRNA accumulation. We used RNAi to downregulate the expression of the major cytoplasmic 5’-3’ exoribonuclease Xrn1 (Fig. 2D). As expected, the capped viral genome was not affected by downregulation of Xrn1 (Fig. 2E). However, the levels of SvsRNA-1, -2, and -3 and their precursors were stabilized (Fig. 2F). We then looked at the effect of combining knockdown of these factors (see Fig. S6 in the supplemental material). We found that the double knockdown of both RNase L and Dicer did not affect the accumulation of SvsRNA-1 compared to the single RNase L knockdown, which confirms that Dicer does not play a role (Fig. S6A). On the contrary, the accumulation of SvsRNA-1 upon double knockdown of both RNase L and Xrn1 increased compared to the single RNase L knockdown (Fig. S6A). This finding suggests that both RNase L and Xrn1 can act upon viral RNAs and have opposite activities in terms of generation and stabilization of the SvsRNAs. Xrn1 might act upstream of RNase L in degrading, for example, uncapped viral RNAs that would otherwise be a substrate for RNase L; alternatively, it could directly act upon the RNase L products. The former hypothesis is more likely though because Xrn1 has a preference for 5’ phosphorolyzed RNAs, whereas RNase L leaves a 5’ OH after cleavage. We also performed a high-molecular-weight Northern blot analysis to look at the effects of the various knockdowns on the cleavage of the genomic and subgenomic viral RNAs. The results confirm the quantitative PCR data, in that only the RNase L KD has an impact on the accumulation of both genomic and subgenomic RNAs (Fig. S6B).

We also tested several cytoplasmic 3’-5’ exoribonucleases, including DIS3L, DIS3L2, and Rrp40 (also known as EXOSC3, a core subunit of the exosome); knockdown of these factors had no effect on SvsRNA accumulation (data not shown). This indicated that at least the main cytoplasmic 3’-5’ exoribonucleases do not seem to be implicated in the production of the viral small RNAs.

**The 3’ extremity of SvsRNA-1 is modified.** RNase L processing produces a typical signature: the enzyme leaves a 5’ hydroxyl (OH) and a 3’ phosphate (P) after cleavage (6). However, these features are not compatible with our small RNA cloning protocol (29), which strictly relies on the presence of a 5’ P and a 3’ OH on the small RNA extremities. This prompted us to characterize the extremities of SvsRNAs to better understand their biogenesis. We initially decided to restrict our analysis to SvsRNA-1 because it accumulated as a major form of 23 nt. The assay used for the analysis of RNA 5’ ends involved digestion with the Terminator exonuclease, a processive 5’-3’ exonuclease that specifically targets and degrades RNAs with a 5’ monophosphate, but not RNAs with 5’ triphosphates, 5’ OH, or a 5’ CAP (30).

For a control, the Terminator reaction was carried out on both a 5’ OH and a 5’ P oligoribonucleotide with the same sequence as SvsRNA-1. Terminator treatment did not result in the degradation of the 5’ OH synthetic oligoribonucleotide, whereas the 5’ P RNA oligonucleotide was almost completely degraded. Accordingly, SvsRNA-1 is prone to degradation by the Terminator exonuclease, which is consistent with the presence of a monophosphate at the 5’ end, while the accumulation of the precursor bands was less affected by the treatment (Fig. 3A).

Next, we performed sodium periodate (NaIO₄) treatment followed by β-elimination to specifically examine the 3’ end of SvsRNA-1. The presence of hydroxyl groups in positions 2’ and

**FIG 2 Effects of RNase L and Xrn1 knockdown on SvsRNA accumulation.** (A and D) RNase L and Xrn1 knockdown in SINV-infected HEK293 cells was verified by Western blotting. Tubulin (Tub) was used as a normalizer. si ctrl, control siRNA; siRNaseL, RNase L-specific siRNA; siXrn1, Xrn1-specific siRNA. (B and E) SINV genomic RNA was quantified by RT-qPCR, before and after RNase L or Xrn1 KD. The relative quantification is normalized to GAPDH levels and is represented on a logarithmic scale as a mean of three replicates. (C and F) Northern blot analysis on total RNA from infected HEK293 cells before and after RNase L or Xrn1 KD. U6 was used as a normalizer.
3’ on the last ribose is needed for the periodate reaction. β-elimination of the oxidized RNA results in an RNA product one or two nucleotides shorter. On the contrary, the presence of modifications on the ribose of the 3’ terminal residue renders the RNA insensitive to periodate oxidation and impairs the chain scission (31). For a control for the reaction, we measured its effect on the unmodified cellular miRNA miR-16. As expected, the electrophoretic mobility of the miRNA strongly changed after treatment (Fig. 3B). This indicated that the presence of a modification on the terminal ribose, most likely in the 3’-OH extremity but that the modification is not due to a mono-phosphate group caused by a direct RNase L cut.

Viral genomic RNA is modified on A8333. The presence of posttranscriptional modifications, such as 2’-O-methylation, is a characteristic of several cellular RNAs in mammals, such as rRNAs (32), snRNAs (33), and Piwi-interacting RNAs (piRNAs) (34, 35). Recently, it has also been reported for several viruses that their genomic RNA can be 2’-O-methylated at specific positions (36, 37). We hypothesized that the modification on the small RNA could be derived from a modification at the level of the genomic RNA, which is reasonable given the fact that SvsRNA-1 precursor RNAs also appear to be modified (see Fig. S7 in the supplemental material). We thus looked for modifications in the genomic region spanning SvsRNA-1 using the RTL-P (reverse transcription at low deoxyribonucleoside triphosphate triphosphate concentrations followed by polymerase chain reaction) technique (38): the tendency of the reverse transcriptase to pause immediately before a 2’-O-methylated nucleotide is exploited to establish the efficiency of retrotranscription by semiquantitative PCR, using differential deoxyribonucleoside triphosphate (dNTP) concentrations.

As shown in Fig. 4A, we designed a reverse transcription primer specific for the viral genome, as well as primers for semiquantitative PCR in the region surrounding SvsRNA-1 (shown in red): one reverse primer (R) and three forward primers, upstream (F1) or downstream of the putative modification (F2D1 and F2D2). After retrotranscription with low and high dNTP concentrations, we performed multiplex PCR using primers F1/F2D1 (in the SvsRNA-1 region) or primers F1D/F2D (in the control region) and then compared the signal intensity ratios of PCR products amplified with different numbers of PCR cycles (Fig. 4B). Our data indicated that only the F1/F2D1 ratio changed depending on the RT conditions (Fig. 4B, top panel), suggesting that at a low dNTP concentration, the reverse transcriptase paused in the SvsRNA-1 region, most probably due to the presence of a modification on the viral genome in the region of interest.

To further strengthen this observation and to identify the precise position of the nucleotide modification, we performed primer extension assays on RNA isolated from either SINV-infected HEK293 or Vero cells (Fig. 4C). 2’-O-methylation can cause reverse transcriptase to pause one nucleotide before and/or at the O-methylated nucleotide. Indeed, we identified two bands (RT stops) that correspond to nucleotides G3334 and A8333, the latter corresponding precisely to the 3’ end of the SvsRNA-1 sequence (Fig. 4C).

These data imply that the 3’-end modification of SvsRNA-1 was likely already present on the viral genome and might be a 2’-O-methylation.

3’-end modification is a hallmark of SvsRNAs. Taken together, our observations indicate that the SINV genomic RNA is modified, and are therefore suggestive of a potential modification of SvsRNAs. We then decided to investigate to what extent reads mapping to the SINV genome were modified at the last nucleotide position. Small RNA libraries were prepared from noninfected or SINV-infected HEK293 cells using total RNA treated (or not) with NaIO4. This treatment specifically impairs the 3’ adapter ligation to RNA species with unmodified 3’ ends (2’ and 3’ OH), while RNAs bearing a modification at one of these positions are resistant to RNA digestion by RNase L. Taken together, these results show that SvsRNA-1 is modified at its 3’ extremity but that the modification is not due to a mono-phosphate group caused by a direct RNase L cut.
to oxidation, and can therefore be ligated. Overnight ligation of the 3’ adapter at 16°C was performed in order to enhance the cloning of 2’-O modified small RNAs (39).

After deep sequencing of these libraries, we mapped the total number of reads against both the human and SINV genome (Table 1). As expected, in both noninfected and infected cells, the NaIO4 treatment drastically reduced the number of clonable miRNA sequences (see also Fig. S9A in the supplemental material). In contrast, modified small RNAs (such as tRNA fragments) were preferentially cloned over miRNAs upon NaIO4 treatment (Fig. S9B). Strikingly, almost 75% of the viral reads were kept after oxidation (Table 1). The oxidation treatment did not dramatically change the genomic distribution of the viral reads compared to the nontreated sample (Fig. 5A). However, deep sequencing revealed some new peaks (Fig. 5A, arrows) that we could also validate by β-elimination and Northern blot analysis (see SvsRNA-15 and -16 in Fig. S8).

The size distribution of the viral reads remained unchanged before and after NaIO4 treatment, indicating that SINV-derived modified RNAs belonged to each length (Fig. 5B). Finally, we analyzed the nucleotide composition of the 3’ end of SINV small RNAs and observed that we had enrichment in adenosine (A) at the 3’ end after oxidation, which was not clearly discernible in the nontreated sample (Fig. 5C). This is in line with the specific 2’-O-methylation occurring on internal adenosines recently identified on the genome of dengue virus (36).

DISCUSSION

Mammals have evolved a very sophisticated innate immune response to ward off pathogens that is based on the sensing of pathogen-associated molecular patterns (PAMPs) by dedicated pattern recognition receptors (PRRs). When it comes to viral infection, one of the most potent PAMPs is dsRNA. The recognition of dsRNA by PRRs triggers a signaling cascade that ultimately leads to the activation of interferon-sensitive genes (ISGs) (40). RNA silencing is another type of antiviral innate immunity, which, as of now, has mostly been demonstrated in plant and insect organisms (1). Nonetheless, a role for RNA silencing as a host defense system against mammalian viruses could reasonably be considered. Indeed, Dicer, the key enzyme for dsRNA cleavage is conserved in higher vertebrates, and although its main substrate in vivo is pre-miRNA molecules, it is able to process long dsRNA into short RNAs in vitro (41). However, the question as to which other types of dsRNA molecules mammalian Dicer can cleave in vivo has been the matter of intense research, and especially so when considering RNAs of viral origin. Here, we wanted to make our contribution to the field by studying the prototypical arbovirus, Sindbis virus. This type of virus can infect both insects and mammals, and as such is a useful tool to study the conservation of antiviral mechanisms in both phyla. Intriguingly, it has been shown for some members of the alphavirus genus that their Figure 4 SINV genomic RNA is modified. (A) Schematic diagram of the primer design for RTL-P to detect the presence of 2’-O-methylated nucleotides (m) on the viral genome. SvsRNA-1 is indicated in red. (B) Detection of methyl- ation by RTL-P under both high and low dNTP concentrations and PCR cycles on SINV-infected HEK293 cells. The ratio of PCR signal intensity is indicated beneath each lane. (C) Primer extension mapping of 2’-O-methylated nucleotides. Lanes U, G, C, and A represent dideoxy sequencing reactions performed on the in vitro transcript amplified for the same viral region. Asterisks indicate stops of the reverse transcriptase.

(Continued)
genomic RNA can be processed into both siRNAs and piRNAs in insect somatic cells (42, 43).

In this study, we generated small RNA libraries from two different mammalian cell lines infected with SINV. Although the percentage of sequences mapping to the viral genome was significant (~1.7 to ~8% in HEK293 and Vero cells, respectively), we were unable to detect either siRNA or piRNA signatures. On the contrary, the viral reads displayed a highly biased strand distribution. Although antigenomic (negative) strand-derived sequences represented a very small percentage of the total viral reads, they showed properties distinct from the genomic (positive) strand reads: their size distribution peaked at 22 nt, and their localization on the viral genome is restricted to the promoters required for the synthesis of both the genomic and subgenomic RNA. Although the cloned 22-nt sequences were not visible by Northern blot analysis, they originate from the same viral genomic positions in both insect and mammalian cells (42, 43).

We therefore focused on the characterization of the positive-strand-derived small RNAs. One hypothesis regarding their identity could be that some of these SvsRNAs are in fact virus-encoded miRNAs. Using bioinformatics tools such as miRDeep2 (45, 46) and miRanalyzer2 (47, 48), we excluded the possibility that putative miRNA precursor structures were present in the viral genome. Nonetheless, we tested whether the miRNA machinery was required for the production of viral small RNAs by knocking down Drosha, Dicer, and Ago2. The downregulation of these factors affected neither SINV replication nor accumulation of the three most abundant identified SvsRNAs, indicating that their production must involve another RNase. We discovered that the RNase L endonuclease is implicated in SvsRNA genesis. Indeed, its downregulation causes a dramatic reduction in the accumulation of Sindbis viral small RNAs detected by Northern blot analysis; this is accompanied by an upregulation of the viral genomic RNA. In order to extend this observation, we also generated small RNA libraries from HEK293 cells treated with siRNAs against RNase L and infected with SINV. We found that, under these conditions, the global population of SINV sRNAs was downregulated. RNase L is an endoribonuclease that is present in the cell in the form of an inactive monomer. Upon type I interferon induction, and more specifically 2'-5' oligoadenylate synthetase activation (6), it can dimerize and then act upon its viral RNA targets. RNase L is known to play an antiviral role against viruses such as West Nile virus (49), hepatitis C virus (50), and SINV (51). We also looked at the involvement of exoribonucleases in the production of SvsRNAs and found that, indeed, the accumulation of these small RNAs is counteracted by the cellular 5’-3’ exonuclease Xrn1. This suggests that SvsRNAs represent stable viral products of cellular decay enzymes. We therefore hypothesize that RNase L is the enzyme primarily involved in the generation of small RNAs and that the further processing operated by other uncharacterized enzymes could give rise to the final 20- to 30-nt-long viral RNAs. It also remains possible that some of the fragments we detected are direct products of RNase L but are further modified by kinases and dephosphorylases, which would allow their cloning.

The fact that RNA fragments generated by RNase L are detected implies that some of them must be stabilized. Indeed, we discovered that the viral small RNA candidates appear to be modified on the 3’ proximal nucleotide. We could extend this peculiarity to the global small RNA population by cloning and sequencing small RNAs after an oxidation treatment designed to prevent ligation of nonmodified RNAs. Our data indicate that this

### TABLE 1 Deep sequencing results of NaIO₄-treated and nontreated small RNA libraries

| Category       | HEK293-NI-NT | HEK293-NI-NaIO₄ | HEK293-SINV-NT | HEK293-SINV-NaIO₄ |
|----------------|--------------|-----------------|---------------|-------------------|
| Raw data       | 21,631,645   | 34,131,455      | 20,753,238    | 28,263,345        |
| Filtered out   | 92,556       | 3,589,935       | 146,674       | 5,425,669         |
| Unmapped       | 840,747      | 7,135,376       | 1,276,025     | 5,143,518         |
| Mapped         | 20,698,342   | 23,406,144      | 19,330,539    | 17,694,158        |
| hsa miRNAs     | 18,286,004   | 88.40           | 7,325,147     | 31.30             |
| hsa tRNAs      | 66,614       | 0.32            | 1,509,137     | 6.45              |
| hsa tRNAs      | 878,642      | 4.24            | 6,260,105     | 26.75             |
| hsa snRNAs     | 8,956        | 0.04            | 13,719        | 0.06              |
| hsa snORNs     | 91,453       | 0.44            | 93,919        | 0.40              |
| hsa miscRNAs   | 59,911       | 0.29            | 36,831        | 0.16              |
| Only viral RNA | 491          | 0.00            | 37            | 0.00              |
| Unannotated RNA| 1,294,251    | 6.25            | 8,167,249     | 34.89             |

* Abbreviations: hsa, homo sapiens; miscRNAs, miscellaneous RNAs.
modification is most likely a 2′-O-methylation and seems to occur at the level of the viral genomic RNA, preferentially on adenosines.

Thanks to a double approach of RTL-P and primer extension, we were able to map such a modification on position A8333 of the SINV viral genome. Moreover, our sequencing data indicate that there are most likely many others given the enrichment in A residues at the 3′ end of small RNAs cloned after oxidative treatment.

The main protective mechanism against 3′-5′ degradation is a 2′-O-methylation on the 3′ proximal ribose, which prevents degradation by exoribonucleases and thus helps to stabilize small RNAs such as miRNAs and siRNAs in plants, piRNAs in animals, and siRNAs in Drosophila melanogaster (52). This suggests that RNA modification could have evolved as a response to protect the anti-pathogen small RNAs during infections. Posttranscriptional RNA modifications represent an important but not yet fully understood system to regulate transcripts. Cellular RNAs contain many distinct posttranscriptional modifications at thousands of sites. In the same way, RNA viruses take advantage of nucleoside modifications on the base or on the ribose of their genomic RNA (36, 53) as a host mimicry strategy to abrogate innate immune signaling (54).

The enzyme responsible for the methylation of SINV RNA remains unknown. However, it has been reported that the alphavirus nsP2 protein contains a putative methyltransferase (MT)-like domain, similar to dengue virus NS5 MTase (55). Although the activity of this domain has not been verified yet, nsP2-MTase mutant viruses exhibit a strong phenotype: negative-strand synthesis is continuous, and unstable viral replication complexes are produced. Surprisingly, RNase L-deficient cells infected with SINV display the same phenotype, suggesting that the two proteins function in similar events (55). For all these reasons, we propose that RNase L-dependent, 3′-modified small RNAs from SINV could be involved as intermediates in this mechanism.

Altogether, our findings show a link between the host degradation pathway and stabilization of modified viral small RNAs. Clearly, not all the small RNAs identified by our deep sequencing approach correspond to RNase L downstream products. Nonetheless, the fact that at least some of these small RNAs are protected and detected might implicate them in signaling events, maybe upstream of the infection front, which might prove difficult to assess in cell culture. We hypothesized that by removing RNase L we might uncover signatures corresponding to other types of small RNAs, such as siRNAs or piRNAs, but it did not turn out to be the case. This could be due to the fact that other enzymes might also be involved in the production of RNA fragments and is an indication that it will make the detection of antiviral RNAi complicated in differentiated mammalian cells. An alternate hypothesis could also be that SINV encodes an RNA silencing suppressor that blocks Dicer activity but has no effect on RNase L. Finally, it is also possible that the antiviral RNAi response might be detected only in specific subtypes of cells in mammals, which would be different from the differentiated somatic cells we used for our study. Further investigation will be needed to answer these questions and to decipher the roles played by this type of virus-derived small RNAs, as well as their potential implication in the design of new antiviral therapeutic strategies.

MATERIALS AND METHODS

Viral stocks, cell culture, and virus infection. Plasmid carrying wild-type (WT) and green fluorescent protein (GFP)-SINV genomic sequence
RNAi-mediated protein depletion. For siRNA transfection, 0.4 × 10^5 HEK293 cells were seeded in 6-well plates. Transfections were carried out for 72 h using 20 nM ON-TARGET plus Smart Pool siRNAs (Dharmacon) for one-step depletion (human RNase L and Xrn1) or 100 nM ON-TARGET plus Smart Pool siRNAs (Dharmacon) for two-step depletion (human Drosha, Dicer, and Ago2) with Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions. The ON-TARGET plus Non-targeting Pool siRNAs (Dharmacon) was used as a negative control. Cells were infected with SINV and harvested after 16 h for RNA and protein analysis.

Small RNA cloning and sequencing. RNA was extracted from noninfected and SINV-infected HEK293 and Vero cells 16 hpi. Small RNA cloning was conducted with 10 or 20 μg of total RNA, as previously described (14, 29). Small RNA libraries from SINV-infected HEK293 cells treated with control or RNAi-specific siRNAs were generated following the same protocol with some modifications. Mainly, small RNAs were ligated using degenerate 5′ and 3′ adapters to limit biases in the ligation step (56). This procedure was also used to prepare small RNA libraries after NaOCl treatment of 100 μg of total RNA, as previously described (57), except that the 3′ ligation was performed at 16°C overnight, in 12% polyethylene glycol 8000 (PEG 8000) to favor the cloning of modified small RNAs. Sequencing was performed at the IGBMC Microarray and Sequencing platform, Illkirch, France, using different Illumina instruments (Genome Analyzer Ix, HiSeq 2000, and HiSeq 2500) with a read length of 36 or 50 bp.

A detailed description of the deep sequencing data analysis is available in Text S1 in the supplemental material.

Microarray data accession number. The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (GEO) through GEO Series accession number GSE48831 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48831).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at http://mbio.asm.org/cgi/lookup/suppl/doi:10.1128/mBio.00698-13/-/DCSupplemental.

Text S1, DOC file, 0.1 MB.

Figure S1, TIF file, 1 MB.

Figure S2, TIF file, 0.8 MB.

Figure S3, TIF file, 1.8 MB.

Figure S4, TIF file, 1.5 MB.

Figure S5, TIF file, 0.6 MB.

Figure S6, TIF file, 2.6 MB.

Figure S7, TIF file, 2.6 MB.

Figure S8, TIF file, 2.4 MB.

Figure S9, TIF file, 0.8 MB.

ACKNOWLEDGMENTS

This work was supported by an ATIP starting grant from CNRS, Agence Nationale pour la Recherche sur le Sida et les Hépatites Virales (ANRS-2009-136), Agence Nationale pour la Recherche (labex netRNA, ANR-10-LABX-36), and the European Research Council (ERC starting grant nrRNAVIR 260767).

We are grateful to M. C. Saleh for the gift of the plasmids for SINV preparation and G. Meister for the anti-Ago2 antibody. We thank Frédéric Gros for technical help with the fluorescence-activated cell sorting (FACS) analyses. We acknowledge Valérie Cognat and the Biolmage facility (IBMP, Strasbourg, France) for help with the initial analysis of the deep sequencing data. We also thank the IGBMC Microarray and Sequencing platform, member of the France Genomique program, for the sequencing of our libraries. We thank all members of the Pfeffer laboratory, especially Lee Tuddenham for critically reading the manuscript and Gabrielle Haas for fruitful discussions.

REFERENCES

1. Ding SW, Voinnet O. 2007. Antiviral immunity directed by small RNAs. Cell 130:413–426.

2. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131–139.

3. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783–801.

4. Borden EC, Sen GC, Uze G, Silverman RH, Ranshoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6:975–990.

5. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 95:15623–15628.

6. Silverman RH. 2007. Viral encounters with 2′,5′-oligoadenylate synthetase and RNA I during the interferon antiviral response. J. Virol. 81:12720–12729.

7. Parameswaran P, Sklan E, Wilkins C, Burgon T, Samuel MA, Lu R, Ansel RM, Heissmeyer V, Einar S, Jackson W, Doukas T, Paranjape S, Penn情侣, dos Santos S, Fallali R, Babaradzadeh F, Gharizadeh B, Grimm D, Kay M, Koike S, Sarnow P, Ronaghi M, Ding SW, Harris E, Chow M, Diamond MS, Kirkegaard K, Glenn JS, Fire AZ. 2010. Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog. 6:e1000764. doi:10.1371/journal.ppat.1000764.

8. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschi T, Zamore PD. 2001. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293:834–838.

9. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rädmark O, Kim S, Kim VN. 2003. The nuclear RNA III Drosha initiates microRNA processing. Nature 425:415–419.

10. Krol J, Loedige I, Filipowicz W. 2010. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11:957–960.

11. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Saïb A, Voinnet O. 2005. Identification of microRNAs of the herpesvirus family. Nat. Meth 2:269 –276.

12. Lecellier CH, Dunoyer P, Arar K, Lehmann-Ché J, Eyquem S, Himber C, Saib A, Voinnet O. 2005. A cellular microRNA mediates antiviral defense in human cells. Science 308:557–560.

13. Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C, Tuschi T. 2004. Identification of virus-encoded microRNAs. Science 304:734 –736.

14. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. 2005. Identification of microRNAs of the herpesvirus family. Nat. Methods 2:269–276.

15. Cai X, Lu S, Zhang G, Gonzalez CM, Damania B, Cullen BR. 2005. Kaposi’s sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U. S. A. 102:5570–5575.

16. Samols MA, Hu J, Skalsky RL, Renne R. 2005. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 79:9301–9305.

17. Tuddenham L, Jung JS, Chane-Woon-Ming B, Dölken L, Pfeffer S. 2005. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 79:9301–9305.

18. Shapiro JS, Varble A, Pham AM, tenOever BR. 2010. Noncanonical cytoplasmic processing of viral microRNAs. RNA 16:2068–2074.

19. Shapiro JS, Langlois RA, Pham AM, tenOever BR. 2012. Evidence for a cytoplasmic microprocessor of pri-microRNAs. RNA 18:1338–1346.

20. Griffin DE. 2007. Alphaviruses, p 1023–1068. In Knipe DM, Howley PM,
Griffin DE, Lamb RA, Martin MA, Roizman B, Strauss SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

23. Akhraymuk I, Kulemzin SV, Frolova EI. 2012. Evasion of the innate immune response: the Old World alphavirus nsP2 protein induces rapid degradation of Rbp1, a catalytic subunit of RNA polymerase II. J. Virol. 86:7180–7191.

24. Strauss JH, Strauss EG. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58:491–562.

25. Jose J, Snyder JE, Kuhn RJ. 2009. A structural and functional perspective of alphavirus replication and assembly. Future Microbiol. 4:837–856.

26. Desmyter J, Melnick JL, Rawls WE. 2007. Identification of virally encoded microRNAs in seven animal clades. Nucleic Acids Res. 35:37–52.

27. Behm-Ansmant I, Helm M, Motorin Y. 2006. Interferon action: RNA degradation of Rpb1, a catalytic subunit of RNA polymerase II. J. Virol. 80:2987–2999.

28. Behm-Ansmant I, Helm M, Motorin Y. 2011. Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribosome 2′-O-methylation by nsp16/nsp10 complex. PLoS Pathog. 7:e1002294. doi:10.1371/journal.ppat.1002294.

29. Munafó DB, Robb GB. 2010. Optimization of enzymatic reaction conditions for generating representative pools of cDNA from small RNA. RNA 16:2537–2552.

30. Beutler B, Eidenschink C, Crozat K, Imler JL, Takeuchi O, Hoffmann IA, Akira S. 2007. Genetic analysis of resistance to viral infection. Nat. Rev. Immunol. 7:753–766.

31. Hammond SM. 2005. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 579:5822–5829.

32. Morazzani EM, Wiley MR, Murreddu MG, Adelman ZN, Myles KM. 2012. Production of virus-derived ping-pong-dependent piRNA-like small RNAs in the mosquito soma. PLoS Pathog. 8:e1002470. doi:10.1371/journal.ppat.1002470.

33. Ummesh-H, Yen HL, Poon LL, Callen BR. 2010. Influenza A virus expresses high levels of an unusual class of small viral leader RNAs in infected cells. mBio 1(4):e00204-10. doi:10.1128/mBio.00204-10.

34. Vidovic-M, Kuremashima M, Zhan MS, Ishihara T. 2012. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 40:37–52.

35. Griffin DE, Lamb RA, Martin MA, Roizman B, Strauss SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

36. Malmberg JW, Shao P, Diao LT, Zhou H, Yu CH, Qu LH. 2007. Genetic analysis of resistance to viral infection. Nat. Rev. Immunol. 7:753–766.

37. Chen J, Yu C, Ke M, Jin X, Xu L, Zhang Z, Wu A, Sun Y, Yang Z, Tien P, Aholta T, Liang Y, Liu X, Guo D. 2011. Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribosome 2′-O-methylation by nsp16/nsp10 complex. PLoS Pathog. 7:e1002294. doi:10.1371/journal.ppat.1002294.

38. Daffis S, Szejafter KL, Schrewer J, Li J, Youn S, Errett J, Lin TY, Schneller S, Zuck R, Dong H, Thi V, Sen GC, Fensterl V, Klimstra WB, Pierson TC, Buller GM, Gale M, Shi PY, Diamond MS. 2010. 2′-O-methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468:452–456.

39. Mayrup, Geders TW, Smith JL, Kuhn RJ. 2008. Role for conserved residues of Sindbis virus nonstructural protein 2 methyltransferase-like domain in regulation of minus-strand synthesis and development of cytopathic infection. J. Virol. 82:2784–2797.

40. Sorefan K, Pais H, Hall AE, Kozomara A, Griffiths-Jones S, Moulton V, Dalmay T. 2012. Reducing ligation bias of small RNAs in libraries for next-generation sequencing experiments. Nucleic Acids Res. 37:e28–W76.

41. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210.

42. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406–3415.